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ABSTRACT: Monocationic and dicationic cholinium ionic
liquids (ILs) were synthesized and evaluated as acetylcholi-
nesterase (AChE) inhibitors with in vitro and in silico models,
and their cytotoxicity was assessed using human cell lines
from skin (CRL-1502) and colon cancer (CaCo-2). The ILs
with a longer alkyl chain were stronger AChE inhibitors, the
dicationic ILs (DILs) being more active than the mono-
cationic ILs. The best result was obtained for
[N1,1,12,2(OH)]2Br2 at a concentration of 0.18 μM by reducing
half enzyme activity without affecting the viability of tested
cell lines. A saturation-transfer difference NMR (STD-NMR)
binding study was carried out, demonstrating that
[N1,1,12,2(OH)]2Br2 binds to AChE. STD-NMR competition
binding experiments, using galanthamine as a reference ligand, clearly highlight that the IL displaces galanthamine in the AChE
binding site pinpointing [N1,1,12,2(OH)]2Br2 inside the deep gorge of AChE. In order to obtain a three-dimensional (3D) view of
the molecular recognition process, in silico molecular docking studies on the active site of AChE were carried out. The
proposed 3D model of the AChE/DIL complex is in agreement with the STD-derived epitope mapping, which explains the
competition with galanthamine and unveils key interactions in both peripheral and catalytic sites of AChE. These interactions
seem essential to govern the recognition of DILs by the AChE enzyme. Our study provides a structural and functional platform
that can be used for the rational design of choline-based ILs as potent AChE inhibitors.
1. INTRODUCTION
Acetylcholinesterase (AChE) is a member of the α/β
hydrolase protein super family, which catalyzes the hydrolysis
of acetylcholine (ACh) in the cholinergic synapses.1−4 In the
peripheral nervous system, ACh mediates nerve impulse in
neuromuscular junctions and is a major neurotransmitter in the
autonomic nervous system controlling memory and learning
processes.5 There has been a growing interest in AChE because
of its importance in neurodegenerative diseases such as
Alzheimer’s disease (AD). A deficiency in ACh is linked to
the pathogenesis of AD, resulting in a decline in memory and
recognition.6−9
AChE contains various binding domainscatalytic, anionic,
acyclic, oxyanionic, and peripheral anionic. The first domain is
situated at the bottom of 20 Å deep and narrow binding gorge
and contains the catalytic triad composed by Ser203, Glu334,
and His447. The anionic domain is formed by four aromatic
residuesTrp86, Tyr130, Tyr337, and Phe338 and is the
binding site for the quaternary trimethylammonium choline
moiety. The acyl domain is constituted by two bulky
residuesPhe295 and Phe297 that are responsible for the
selective binding of ACh. The oxyanionic hole is formed by
Gly121, Gly122, and Ala204 and hosts one molecule of
structural water, which is responsible for the formation of a
hydrogen bond between the enzyme and substrate stabilizing
the substrate tetrahedral transition state. The peripheral
anionic site (PAS) is one of the most important drug target
binding sites and is located at the entrance to the binding
gorge presenting five residuesTyr72, Asp74, Tyr124,
Trp286, and Tyr341. PAS participates in noncholinergic
functions as amyloid deposition, and therefore, inhibitors
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that bind to both catalytic site and PAS are crucial for AD
treatment.4,10
AChE inhibitors, such as rivastigmine, donepezil, tacrine,
and galantamine, approved by Food and Drug Administration
present some drawbacks. Tacrine induces significant liver
toxicity and the others seem inefficient to block or slow down
the progress of AD.6,8,11−14 Several new inhibitors have been
documented being hybrid molecules relevant compounds on
AChE inhibition.10,14,15
Quaternary and bis-quaternary ammonium salts have been
investigated as AChE inhibitors, which include pyridinium,
quinolinium, isoquinolinium, and quinuclidinium as cati-
ons.5,9,11,13,16−22 Additionally, ionic liquids (ILs) have also
been investigated as AChE inhibitors.23−28 It has been
demonstrated that the potency of AChE inhibition by ILs
depends on the positively charged nitrogen atom, a widely
delocalized aromatic system, and the lipophilicity of the side
chains connected to the cationic head groups, the last one
being identified as a potent structural element for AChE
inhibition.23,29 Stock et al. have shown that pyridinium-based
ILs induced a stronger inhibition than imidazolium-based
ILs.24 Moreover, Arning and co-workers observed that
quinolinium-based ILs together with dimethylaminopyridi-
nium were stronger AChE inhibitors than morpholinium-based
ILs.23
The influence of dicationic ILs (DILs) on AChE activity was
also addressed.28 Similar to monocationic imidazolium-based
ILs, increasing the side-chain length also leads to a higher
inhibitory potential of the DILs.23,28 However, DILs are less
potent inhibitors when compared to the corresponding
monocationic ILs.28
The search for more potent and AChE inhibitors is still
ongoing, and the “greener” choline-based ILs have gained
particular attention.30,31 We studied the impact of mono- and
dicholine-based ILs with different chain lengths and chemical
functionalities on AChE activity and evaluated the cytotoxicity
on human cell lines from skin (CRL-1502) and intestinal
cancer (CaCo-2). In addition, we report NMR spectroscopy
binding studies of the DIL [N1,1,12,2(OH)]2Br2 versus AChE. In
particular, we have employed saturation-transfer difference
NMR (STD-NMR) to evaluate the binding of DIL to AChE
and to determine the binding epitope mapping. In addition,
STD-NMR competition binding experiments using the well-
studied inhibitor galanthamine as a reference ligand were
performed to assess the DIL binding site. Finally, NMR-
derived data were combined with molecular docking to obtain
a 3D model of the AChE/DIL complex structure.
2. METHODS AND MATERIALS
2.1. Chemicals. All chemicals, reagents, and solvents for
the synthesis of the compounds were of analytical grade,
purchased from commercial sources, namely, Sigma-Aldrich,
Merck, and Alfa Aesar, and were used without further
purification. AChE-type VI-S, from electric eel 349 U/mg
solid, 411 U/mg protein, and acetylthiocholine iodide (AChI,
≥98%) were purchased from Sigma-Aldrich. 5,5′-Dithio-bis-
(2-nitrobenzoic acid) (DTNB) was purchased from VWR
International Prolabo. 1,2,3,4-Tetrahydro-5-aminoacridine
(Tacrine) was obtained from Cayman Chemical Company.
The compounds 1,14-dibromotetradecane and 1,6-dibromo-
hexadecane were synthesized with some modifications of the
reported procedure.32 1H and 13C NMR spectra were recorded
Table 1. Mono-Quaternary Ammonium Salt Choline Derivatives (Series A−B)
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on an Ultrashield Bruker AVANCE II 300 spectrometer, an
Ultrashield Bruker AVANCE II 400 spectrometer, and a
Bruker Fourier 300 spectrometer. Splitting patterns are
indicated as s, singlet; d, doublet; t, triplet; q, quartet; m,
multiplet; br, broad peak. The low-resolution electrospray
ionization (ESI) mass spectra were recorded using a
Micromass Quattro Micro triple quadruple (Waters, Ireland)
with an ESI ion source. High-resolution mass spectroscopy was
performed in a Bruker micrOTOF mass spectrometer, with an
ESI ion source, and in a LTQ Orbitrap XL mass spectrometer
(Thermo Fischer Scientific, Bremen, Germany). Elemental
analysis was performed in a FLASH 2000 CHNS-O analyzer
(Thermo Scientific, UK). The general procedure was adopted
for the samples submitted to elemental analysis, which were
first kept overnight under vacuum line (rotatory pump, below
0.5 mbar) and then kept at room temperature for 3−5 days in
a dedicated vacuum line (rotatory pump, below 0.2 mbar).
Melting points were determined on a Stuart SMP10 apparatus.
2.1.1. General Procedure for the Preparation of
Quaternary and Bis-Quaternary Ammonium Salts. The
quaternary ammonium salts were synthesized by amine
alkylation with the selected alkyl halide. The mono-quaternary
ammonium salts from series A (Table 1) and series B (Table
1), with exception of compounds [N1,1,Cycl,2(OH)]Br,
[N1,morf,2(OH)]Br, [N0,12,2(OH),2(OH)]Br, and [N0,16,2(OH),2(OH)]Br,
have been previously reported by us.33,34 The salts
[N1,1,Cycl,2(OH)]Br, [N1,morf,2(OH)]Br, and [N0,16,2(OH),2(OH)]Br
were prepared with some modifications of the literature,35−37
and together with the new IL [N0,12,2(OH),2(OH)]Br, they are
described in detail in the Supporting Information.
The bis-quaternary ammonium salts (series C−D; Table 2)
were prepared following the same strategy as the mono-
quaternary ammonium salts. The synthesis and character-
ization of the compounds [N1,8−12,2(OH),2(OH)]2Br2 and
[N6−12,2(OH),2(OH)2(OH)]2Br2 have been previously published
by our group.33 For the new bis-quaternary ammonium salts
[N1,1,12−16,2(OH)]2Br2, [N1,1,Bn,2(OH)]2Br2, [N1,1,12,2(OCOCH3)]2Br2,
and [NBn,2(OH),2(OH)2(OH)]2Br2, see more details in the
Supporting Information.
Additional experimental details and selected 1H and 13C
NMR spectra are presented in the Supporting Information.
2.2. AChE Inhibition Assay. The AChE inhibition assay
was performed by the Ellman method, as previously described,
with some modifications38,39 with acetylcholine iodide as a
substrate and DTNB. A mixture of N-(2-hydroxyethyl)-
piperazine-N′-ethanesulfonic acid buffer (50 mM, pH 8.0),
sample solution (30 μL), and AChE enzyme (2.5 U/mL, 7.5
μL) was incubated in a 96-well plate for 15 min at 25 °C. The
reaction was then initiated by the addition of AChI (1.20 mM,
22.5 μL) and DTNB (3.03 mM, 142 μL) (n = 3). The
hydrolysis of acetylthiocholine was monitored, every 30 s for 3
min, by the formation of a yellow 5-thio-2-nitrobenzoate anion
as a result of the reaction of DTNB with thiocholine, produced
by the enzymatic hydrolysis of acetylthiocholine, at a
wavelength of 405 nm, using a 96-well microplate plate reader
(Multiskan FC Thermo Fisher Scientific). Tacrine was used as
positive control and sample solvent as negative control.
The inhibition percentage was determined using the
following equations:
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It is known that for a the velocity reaction of negative
control (ΔAbs405nm/min) should be linear and hence close to
0.060.
2.3. Cell Culture. Human colorectal adenocarcinoma cells
(CaCo-2) and human normal skin fibroblast cells (CRL-1502),
purchased from the American Type Culture Collection
(ATCC), were grown in RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS) and antibiotic−antimycotic
solution. They were kept in 75 cm2 tissue culture flasks and in
an incubator with a humidified 5% CO2 atmosphere at 37 °C.
2.3.1. Toxicity Assay. A total of 96-well plates with 3−4
days of postconfluent differentiated CaCo-2 cells were treated
with the ILs at 1 mM concentration for a 24 h period.
Solutions were prepared with fresh 0.5% FBS supplemented
medium. After the removal of compounds, cell viability was
assessed with the neutral red reagent. IL-treated medium was
removed, and cells were washed with phosphate buffer saline
Table 2. Range of Bis-Quaternary Ammonium Salt Choline Derivatives (Series C−D)
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(PBS) before treatment with 50 μg/mL neutral red for 15 min.
After this period, cells were washed with PBS and incubated
with an organic solution (49% water, 50% ethanol, and 1%
glacial acetic acid) for the quantification of absorbed neutral
red dye. Dye was measured spectrophotometrically at 540 nm
after gentle shaking of the plate. Viability was calculated as the
ratio of the absorbance of treated and untreated cells. Each
experimental condition was done in triplicate. Compounds
were considered not toxic (NT), toxic (T), or very toxic (VT)
when cytotoxicity was below 50, 50−80%, or was above 80%,
respectively.
CRL-1502 cells were treated likewise, but compounds were
added soon after the formation of the monolayer and neutral
red was left in contact with these cells for a period of 3 h.
2.4. Molecular Docking. AChE 3.10 Å resolution
crystallographic structure was obtained from the Protein
Data Bank with code 4BDT. Prior to docking studies, the
cocrystallized inhibitor and water molecules were removed.
The Protonate-3D tool from Molecular Operating Environ-
ment (MOE) 2014 software package40 was used to protonate
AChE, considering His 447 basic tautomer, and then
MMFF94x force field was applied for energy minimization.
Molecular docking studies were performed using GOLD 5.2
software package, namely, the GoldScore scoring function in
which each molecule is subjected to 2000 docking runs, at a 10
Å distance from the Trp86 N atom, was considered the active
site center coordinate. To validate the above-described docking
protocol of the 4BDT, the cocrystallized inhibitor, huprine W,
was docked using this methodology, and the root-mean-square
deviation value between docked and crystallographic poses
obtained was 1.27 Å. For the molecules studied, the 10 highest
gold scored docking poses were visually inspected, and both
were highly superposable, the presented result (Figure 3) being
the highest scored pose.
2.5. NMR Spectroscopy Experiments. NMR spectros-
copy experiments were recorded on a Bruker AVANCE 600
MHz spectrometer with a 5 mm triple-resonance cryogenic
probe head. All experiments were carried out at 298 K using
PBS (20 mM) buffer at pH 7.5. For NMR studies, AChE was
used from the eel Electrophorus electricus from Sigma-Aldrich,
which is a tetramer composed by four equal subunits of 70 kDa
each (each subunit holds one active site).
STD-NMR experiments were carried out for a protein/DIL
molar ratio of 1:30 with a final concentration of 10 μM protein
and 300 μM DIL. To confirm protein specificity, protein
concentration was raised to 20 μM by maintaining constant
Table 3. AChE Enzymatic Inhibition and Cytotoxicity toward Human Cell Linesa
compound concentration (mM) inhibition ± SD (100 μg/mL) IC50 (μM) CRL-1502 (1 mM) CaCo-2 (1 mM)
[N1,1,2,2(OH)]Br 0.505 6.92 ± 1.83 - NT NT
[N1,1,3,2(OH)]Br 0.471 52.5 ± 2.04 - NT NT
[N1,1,4,2(OH)]Br 0.442 63.8 ± 3.65 - NT NT
[N1,1,5,2(OH)]Br 0.416 16.9 ± 3.91 - NT NT
[N1,1,6,2(OH)]Br 0.393 25.6 ± 1.63 - NT NT
[N1,1,8,2(OH)]Br 0.354 49.2 ± 0.74 - NT NT
[N1,1,10,2(OH)]Br 0.322 88.7 ± 2.99 48.5 VT NT
[N1,1,12,2(OH)]Br 0.296 96.4 ± 1.98 13.8 ND T
[N1,1,14,2(OH)]Br 0.273 100 ± 1.28 6.00 VT VT
[N1,1,16,2(OH)]Br 0.273 99.3 ± 0.81 5.94 VT NT
[N1,1,3,2(OH)]Br 0.476 47.6 ± 1.27 - NT NT
[N1,1,6,2(OH)]Br 0.397 28.5 ± 1.50 - NT NT
[N1,1,3,2(OH)]Br 0.481 51.0 ± 1.35 - NT NT
[N1,1,Cycl,2(OH)]Br 0.397 31.5 ± 2.62 - NT NT
[N1,morf,2(OH)]Br 0.442 23.9 ± 1.14 - NT NT
[N0,3,2(OH),2(OH)]Br 0.438 55.5 ± 2.59 - NT NT
[N0,12,2(OH),2(OH)]Br 0.282 98.0 ± 0.92 32.5 ND T
[N0,14,2(OH),2(OH)]Br 0.261 95.9 ± 1.46 11.3 VT VT
[N0,16,2(OH),2(OH)]Br 0.244 66.3 ± 5.26 - ND VT
[N1,3,2(OH),2(OH)]Br 0.413 31.5 ± 2.15 - NT NT
[N1,4,2(OH),2(OH)]Br 0.390 66.0 ± 2.18 - NT NT
[N1,6,2(OH),2(OH)]Br 0.352 7.91 ± 1.72 - NT NT
[N1,10,2(OH),2(OH)]Br 0.294 79.6 ± 0.48 58.9 VT VT
[N1,12,2(OH),2(OH)]Br 0.271 92.2 ± 2.67 23.9 VT VT
[N1,14,2(OH),2(OH)]Br 0.252 75.1 ± 2.16 7.87 VT NT
[N1,3,2(OH),2(OH)]Br 0.416 37.4 ± 2.09 - NT NT
[N1,6,2(OH),2(OH)]Br 0.354 19.7 ± 1.79 - NT NT
[N3,2(OH),2(OH),2(OH)]Br 0.370 21.2 ± 2.77 - NT NT
[N4,2(OH),2(OH),2(OH)]Br 0.349 37.1 ± 2.37 - NT VT
[N6,2(OH),2(OH),2(OH)]Br 0.318 38.1 ± 0.62 - ND T
tacrine 0.05 61.9 ± 1.88 0.021 - -
0.018
donepezil NT NT (0.006−0.012)b - -
aCompounds from series A and B were tested at a single dose in each biological assay. bCompounds were considered NT, T, or VT when the
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DIL concentration. The STD-NMR experiments were carried
out following the protocol previously described by us.41
Control experiments were accomplished in two ways: (i)
sample with the ligand in the absence of AChE [to optimize
the frequency for protein saturation (−0.5 ppm) and to ensure
that the ligand signals were not affected] and (ii) sample with
AChE in the absence of DIL. The STD spectrum of DIL in the
absence of AChE shows residual STD response, which was
subtracted during the analysis of the STD in the presence of
AChE. To determine the epitope mapping of DIL, the STD
intensities of each proton were normalized relative to the
proton with the highest STD enhancement. In the binding
competitions with galanthamine, identical STD-NMR setup
was used. All data were processed using TopSpin 3.5 software
(Bruker).
3. RESULTS AND DISCUSSION
Monocationic ILs and dicationic DILs were synthesized and
cytotoxicity was tested in human normal skin fibroblasts (CRL-
1502) and human intestinal adenocarcinoma cells (CaCo-2),
before the assessment of the cell viability.
3.1. AChE Inhibition Assay. 3.1.1. Monocationic Choli-
nium-Based ILs. Monocationic cholinium-based ILs were
synthesized and divided into two series (A and B) and the
difference between them is the number of hydroxyethyl groups
bound to the positively charged nitrogen (Table 1). To
evaluate their potential to inhibit AChE, compounds were
tested at 100 μg/mL in an enzymatic assay with electric eel
AChE. Different structural features were investigated for
structure−activity relationship studies: the length of the alkyl
side chains, the addition of hydroxyethyl groups, and the
insertion of double and triple bonds between carbons in the
side chains. In series A, we also study the presence of cyclic
alkyl side chains, namely, cyclohexyl side chains, and the
presence of a morpholine derivative.
3.1.1.1. Alkyl Side-Chain Length. For both series A and B,
ILs of different alkyl side-chain lengths were synthesized and
tested. Results are shown in Table 3 and clearly demonstrate
that lipophilicity has an enormous impact on the induced
inhibitory activity. In this sense, the inhibition increased with
the increase of the alkyl side-chain length, and this effect was
seen in both series A and B. AChE activity was only gently
decreased when the alkyl side chain R was in the range C2H5−
C8H27 (series A) or the alkyl side chain R
2 was in the range
C3H7−C6H13 (series B). However, for longer alkyl side-chain
lengths, the induced AChE inhibit ion increased
{[N1,1,10−16,2(OH)]Br (series A), [N0,12−14,2(OH),2(OH)]Br, and
[N1,10−14,2(OH),2(OH)]Br (series B)}. The best AChE inhibitory
activity was observed for compounds [N1,1,16,2(OH)]Br (series
A) and [N1,14,2(OH),2(OH)]Br (series B), whose induced
inhibition was approximately 100% at the tested dose and
determined IC50 values were 5.94 and 7.87 μM, respectively. In
general, for both investigated series, we observed high AChE
inhibition from the alkyl side-chain length with 10 or more
carbons, which confirmed the well-known side-chain effect
tendency.23,24
3.1.1.2. Substitution by an Alkyl Chain by a Hydrogen
Atom. Compounds from series B were also synthesized with R1
equal to H. This change allows the study of the cations with
two hydroxyethyl groups, an alkyl side chain and a hydrogen
group. This modification of series B enhanced the IL activity to
some extent: [N0,3,2(OH),2(OH)]Br reduced approximately half of
the enzyme activity, whereas [N1,3,2(OH),2(OH)]Br induced about
30% inhibition (Table 3). In agreement, and for the longest R2
chains, the same general tendency was obtained: at 100 μg/
mL, [N0,14,2(OH),2(OH)]Br was able to abrogate almost all the
enzyme activity; however, [N1,14,2(OH),2(OH)]Br induced about
75% inhibition and determined IC50 values are 11.3 and 7.87
μM, respectively (Table 3).
3.1.1.3. Addition of Hydroxyethyl Groups. In general, we
did not obtain an improvement in activity with the increasing
number of hydroxyethyl groups. For instance, data show that
[N1,1,4,2(OH)]Br, [N1,4,2(OH),2(OH)]Br, and [N4,2(OH),2(OH),2(OH)]
Br led to an inhibition of 64, 66, and 37%, respectively. A
decrease in inhibition was also seen for the IL pair [N1,1,6,2(OH)]
Br and [N1,6,2(OH)2(OH)]Br that inhibited the activity of the
enzyme by 26% and only 8%, respectively. A decrease in
enzymatic inhibition was also demonstrated to some extent
when [N1,1,10,2(OH)]Br was changed to [N1,10,2(OH),2(OH)]Br. We
Table 4. AChE Enzymatic Inhibition and Cytotoxicity toward Human Cell Linesa,b
compound concentration (mM) inhibition ± SD (100 μg/mL) IC50 (μM) CRL-1502 (1 mM) CaCo-2 (1 mM)
[N1,1,12,2(OH)]2Br2 0.198 100 ± 0.72 0.18 ND NT
[N1,1,12,2(OCOCH3)]2Br2 0.182 100 ± 0.15 0.42 ND NT
[N1,1,14,2(OH)]2Br2 0.187 99.0 ± 0.30 36.93 ND T
[N1,1,16,2(OH)]2Br2 0.182 100 ± 1.21 0.68 ND T
[N1,1,Bn,2(OH)]2Br2 0.193 97.3 ± 0.38 3.92 ND NT
[N1,8,2(OH),2(OH)]2Br2 0.196 89.9 ± 1.60 29.1 NT NT
[N1,10,2(OH),2(OH)]2Br2 0.186 100 ± 0.65 1.59 NT NT
[N1,12,2(OH),2(OH)]2Br2 0.177 93.8 ± 2.84 0.61 NT NT
[N6,2(OH),2(OH)2(OH)]2Br2 0.184 93.0 ± 0.21 41.22 NT NT
[N8,2(OH),2(OH)2(OH)]2Br2 0.175 97.9 ± 0.74 16.76 VT NT
[N10,2(OH),2(OH)2(OH)]2Br2 0.167 98.2 ± 1.12 5.21 ND NT
[N12,2(OH),2(OH)2(OH)]2Br2 0.160 100 ± 2.11 5.22 VT VT
[NBn,2(OH),2(OH)2(OH)]2Br2 0.157 100 ± 2.69 11.1 ND T
tacrine 0.05 61.9 ± 1.88 0.021 - -
0.018
donepezil NT NT (0.006−0.012) - -
aCompounds from series C were tested at a single dose in each biological assay. bCompounds were considered NT, T, or VT when the viability
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may then infer that addition of hydroxyethyl groups does not
favor designing of more active ILs, indeed.
3.1.1.4. Insertion of Multiple Covalent Bonds. We also
assessed the impact of the insertion of double and triple
covalent bonds in the alkyl side chain R (series A) and R1 and
R2 (series B). Comparing [N1,1,3,2(OH)]Br with [N1,1,3,2(OH)]Br
and [N1,1,3,2(OH)]Br, we realize that the IL-induced AChE
inhibition is not significantly affected because the determined
inhibition values were 53, 48, and 51%, respectively (Table 3).
The same trend occurred with [N1,1,6,2(OH)]Br and
[N1,1,6,2(OH)]Br that inhibited the tested enzyme by 26 and
29%, respectively (Table 3). Similar effect was obtained for
compounds within series B: [N1 ,3 , 2 (OH) ,2 (OH)]Br,
[N1,3,2(OH),2(OH)]Br, and [N3,2(OH),2(OH),2(OH)]Br gently
reduced the enzyme activity in about 32, 37, and 21%,
respectively (Table 3).
3.1.1.5. Presence of Morpholine and Cyclohexyl in the
Cation. In series A, the presence of a cyclohexyl side-chain R
([N1,1,Cycl,2(OH)]Br) and the presence of a morpholine
derivative ([N1,morf,2(OH)]Br) were also evaluated in the enzyme
activity. The results showed no significant improvement in the
enzyme activity of 31 and 24%, respectively, when compared
with the corresponding hexyl side-chain R, [N1,1,6,2(OH)]Br with
26%.
3.1.2. Dicationic Cholinium-Based ILs. Similar to the
monocationic cholinium-based ILs, different compounds
were produced with differences concerning the length of the
alkyl side chains, the number of hydroxyethyl groups, the
substitution of CH2CH2OH by CH2CH2OCOCH3, and the
presence or absence of a dibenzyl in the spacer instead of a
hydrocarbon chain (see series C−D, Table 2). The DILs were
tested for AChE activity as mentioned previously for the
monocations, and these compounds exhibited clearly a higher
inhibitory activity toward the studied enzyme than the
corresponding monocationic cholinium-based ILs (Tables 2
and 4).
3.1.2.1. Alkyl-Linkage Chain Length. As shown in Table 4,
the activity of DILs improves with the length of the alkyl-
linkage chain. [N1,8,2(OH),2(OH)]2Br2, [N1,10,2(OH),2(OH)]2Br2, and
[N1,12,2(OH),2(OH)]2Br2 led to a determined IC50 of 29.11, 1.59,
and 0.61 μM, respectively. This trend was also observed in the
p r e s e n c e o f a n a d d i t i o n a l h y d r o x y e t h y l :
[N8,2(OH),2(OH),2(OH)]2Br2, [N10,2(OH),2(OH),2(OH)]2Br2, and
[N12,2(OH),2(OH),2(OH)]2Br2 resulted in an IC50 of 16.76, 5.21,
and 5.22 μM, respectively.
3.1.2.2. Addition of Hydroxyethyl Groups. As mentioned in
the previous subsection, the determined high IC50 values
shows that i t i s necessary higher amounts of
[N10,2(OH),2(OH),2(OH)]2Br2 and [N12,2(OH),2(OH),2(OH)]2Br2 than
t h e co r r e s pond i n g [N1 , 1 0 , 2 ( OH ) , 2 ( OH ) ] 2B r 2 and
[N1,12,2(OH),2(OH)]2Br2 to attain 50% of inhibition. However,
the same was not verified for the shorter [N1,8,2(OH),2(OH)]2Br2
and [N8,2(OH),2(OH),2(OH)]2Br2 ILs. Additionally, if we compare
[N1,1,Bn,2(OH)]2Br2 and [NBn,2(OH),2(OH),2(OH)]2Br2, any advant-
age was due to the addition of another hydroxyethyl group
because the determined IC50 values are 3.92 and 11.1 μM,
respectively (Table 4). As previously demonstrated for the
monocationic cholinium-based ILs, the addition of hydrox-
yethyl groups does not seem to favor the designing of more
active ILs.
3.1.2.3. Insertion of Acetyl Groups. In series C, when R is
COCH3 instead of H, the IC50 is just gently affected increasing
from 0.18 to 0.42 μM (Tables 3 and 4), and thus, we conclude
that this structural modification does not improve the design of
more effective inhibitors.
3.1.2.4. Insertion of Benzyl Groups as Spacers. When the
spacer between the cations is two benzyl groups, instead of a
hydrocarbon chain, the induced inhibition toward the tested
e n z ym e i s r e d u c e d : [N 1 , 1 , B n , 2 ( O H ) ] 2 B r 2 a n d
[NBn,2(OH),2(OH),2(OH)]2Br2 produced an IC50 of 3.92 and 11.1
μM that are significantly higher than the IC50 obtained for
[N1,1,12,2(OH)]2Br2 (0.18 μM) (Tables 3 and 4).
Given these results, we may conclude that the DILs are more
promising than the monocationic ILs. Our best results were
obtained for the DILs [N1,1,12,2(OH)]2Br2, [N1,1,12,2(OCOCH3)]2Br2,
[N1,1,16,2(OH)]2Br2, and [N1,12,2(OH),2(OH)]2Br2 with IC50 of 0.18,
0.42, 0.68, and 0.61 μM, with a spacer between the cations of
the C12−C16 chain. When we compared the DILs with the
corresponding monocationic ILs, the IC50 of the DILs is always
lower, as observed for the DIL [N1,1,12,2(OH)]2Br2 with an IC50
of 0.18 μM versus the monocationic ILs [N1,1,12,2(OH)]Br,
[N0,12,2(OH),2(OH)]Br, [N1,12,2(OH),2(OH)]Br (IC50 of 13.81, 32.54,
and 23.96 μM) and the DILs [N1,1,16,2(OH)]2Br2 versus
[N1,1,16,2(OH)]Br with an IC50 of 0.68 versus 5.94 μM. From
our screening of DILs, the best result was obtained for the
compound [N1,1,12,2(OH)]2Br2 with an IC50 of 0.18 μM.
Possibly, both cations may interact with different binding
sites, and the C12 chain seems to be the most suitable length
between these two suggested locations. This proposition agrees
with the literature, which has shown that both catalytic and
PAS sites are important targeted binding sites.10
3.2. STD-NMR Binding Experiments. STD-NMR is a
very popular and robust ligand-based methodology to
investigate receptor−ligand interactions in distinct biological
Figure 1. A) STD-NMR binding experiment of [N1,1,12,2(OH)]2Br2 (300 μM) in the presence of AChE (20 μM) at 298 K. The upper spectrum
corresponds to the reference spectrum (off-resonance spectrum), and the lower spectrum corresponds to the STD spectrum (scaled 32× with
respect to the reference). (B) STD-derived epitope mapping of [N1,1,12,2(OH)]2Br2 in the presence of AChE.
ACS Omega Article
DOI: 10.1021/acsomega.8b02347
ACS Omega 2018, 3, 17145−17154
17150
contexts.41,42 STD-NMR allows to deduce ligand binding, as
well as, to define which part of the ligand is in closer contact
with the receptor, the so-called ligand binding epito-
pe.43(and references cited herein) Indeed, by employing STD-NMR,
we were able to determine the interaction between AChE and
the most promising DIL, the [N1,1,12,2(OH)]2Br2. This IL is
revealed to be the most active inhibitor of AChE activity
without affecting the viability of the tested cells.
Figure 1 shows the STD results obtained for the
[N1,1,12,2(OH)]2Br2/AChE mixture. The STD-NMR spectrum
clearly shows STD signals corresponding to the DIL in the
presence of AChE (Figure 1A). To establish the binding
specificity of the system, STD experiments, recorded at
different concentrations of AChE, were carried out. The
STD signal response clearly increased with the protein
concentration providing the specificity of the binding process
(Figure S11, Supporting Information). The STD-derived
epitope mapping of DIL in the presence of AChE was also
deduced (Figure 1B and see Methods and Materials).
According to the STD-derived epitope mapping, all
[N1,1,12,2(OH)]2Br2 structure is in closer contact with the protein
surface because all protons receive high percentage of
saturation from the protein. This result can be explained if
the binding site of DIL is deeply located inside the gorge of
AChE.
To confirm this hypothesis and to unveil the DIL binding
site in AChE, STD-NMR competition binding experiments
were performed. These experiments allow to determine if two
ligands compete or not for the same binding site of the
protein.44 Therefore, a ligand with a well-defined binding site
and known affinity is normally chosen as a reference. After
addition of the study ligand, a reduction of the intensity of the
STD signals of the reference ligand will be expected, if both
compete for the same binding site of the protein (otherwise
allosteric effects take place). However, if the intensity of STD
signals of the reference ligand remains unperturbed, the study
ligand and the reference ligand bind at different binding sites of
the protein. To determine the binding site of [N1,1,12,2(OH)]2Br2
to AChE, the well-known inhibitor galanthamine was chosen.
Galanthamine was chosen because it binds to AChE in the
deep gorge active site of AChE with an IC50 value of 0.35
μM.45 For that purpose, the STD-NMR experiment of the
mixture AChE/galanthamine with a molar ratio of 1:30 was
first acquired (Figure 2A,B). Further, the intensity variations in
the STD spectra of the AChE/galanthamine mixture were
monitored by adding three different concentrations of the
[N1,1,12,2(OH)]2Br2 (300 μM, 1.2 mM, and 2.4 mM) (Figure
2C−E). After analyzing the STD spectra, it is possible to
deduce that [N1,1,12,2(OH)]2Br2 displaces galanthamine from the
AChE binding site. A decrease in the STD signal intensity of
galanthamine protons occurs after the addition of DIL pointing
out that both ligands compete for the same binding site in
AChE. In addition, a reverse STD competition binding
experiment at a constant AChE/DIL molar ratio with distinct
concentrations of galanthamine (300 μM, 1.2 mM, and 2.4
mM) was also carried out (Figure S12, Supporting
Information). In agreement, the addition of galanthamine
induces a decrease in the intensity of DIL STD signals.
Altogether, the STD results highlight that DIL should bind the
deep gorge of AChE.
3.3. Molecular Modeling. Finally, to obtain a 3D view of
the AChE/DIL complex, we performed in silico molecular
docking studies in the active site of AChE, using GOLD 5.1
software.46 The coordinates of the enzyme structure were
obtained from Protein Data Bank selecting the structure with
accession code 4BDT. AChE has its catalytic triad, Ser-His-
Glu, located at the bottom of a deep and narrow gorge where
the Ser residue acts as a nucleophile to attack the carbonyl
groups of substrates or pseudosubstrate inhibitors.47 The
docked pose for the most active compound [N1,1,12,2(OH)]2Br2
shows that, as anticipated by the STD-derived epitope map,
the dicationic C12 inhibitor is very well accommodated in the
Figure 2. STD competition experiments of AChE/galanthamine at a constant 1:30 M ratio (AChE 10 μM and galanthamine 300 μM) recorded in
a 600 MHz spectrometer at 298 K with distinct concentrations of DIL. Proton signals of galanthamine and [N1,1,12,2(OH)]2Br2 are identified with
letters G and IL, respectively. (A) Reference spectrum (off-resonance) for the mixture AChE/galanthamine with [N1,1,12,2(OH)]2Br2 2400 μM. (B)
STD spectrum of the mixture AChE/galanthamine without DIL. (C) STD spectrum of the AChE/galanthamine mixture with [N1,1,12,2(OH)]2Br2
300 μM. (D) STD spectrum of the AChE/galanthamine mixture with [N1,1,12,2(OH)]2Br2 1200 μM. (E) STD spectrum of the mixture AChE/
galanthamine mixture with [N1,1,12,2(OH)]2Br2 2400 μM.
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enzyme gorge (Figure 3). The proposed binding mode is also
in agreement with the STD competition binding experiments
using galanthamine as a reference ligand. According to our
model, DIL interacts with both PAS and catalytic sites of
AChE. In particular, one of the quaternary amines sits well in
the catalytic site where the cation−π interaction with Trp86 is
observed, and the hydroxyl establishes an H-bond with
Glu202, blocking the action of the catalytic triad, whereas
the other quaternary amine, which is 12 carbons away, sits on
the entrance of the gorge where the cation−π interaction with
Trp286 is observed. The presence of interactions in both PAS
and catalytic sites seems mandatory for the recognition of DILs
as AChE inhibitors.
3.4. Toxicity Evaluation on Human Cell Lines. Tested
ILs were evaluated on human cell lines CRL-1502 and CaCo-2.
Cell monolayers were grown and exposed to a single dose (1
mM) of the compounds for a period of 24 h before the
assessment of cell monolayer viability.
3.4.1. Monocationic Cholinium-Based ILs. 3.4.1.1. Alkyl
Side-Chain Length. As expected, monocationic cholinium-
based ILs induced high levels of cytotoxicity when the alkyl
side chain R (series A) or R2 (series B) was one of the
following chains: C10H21, C12H23, C14H29, and C16H33 (Table
3). This effect is already known in the literature.48,49
3.4.1.2. Substitution by an Alkyl Chain by a Hydrogen
Atom. Data are not very clear about this structural
modification; however, it seems that there is some decrease
in CaCo-2 toxicity when R1 in [N1,12,2(OH),2(OH)]Br is
substituted by a hydrogen atom[N0,12,2(OH),2(OH)]Br (Table
3). However, when the length of the alkyl side chain R2 is
increased to C14H27 (R
1 equal to H and CH3), we obtain high
cytotoxicity in CRL-1502 cells, meaning that the effect seen
previously is possibly less and less evident when the length of
the side-chain R2 increases (Table 3).
3.4.1.3. Addition of Hydroxyethyl Groups. The effect of
this modification is more noticeable. As shown in Table 3, we
did not obtain a significant toxicity for either [N1,1,4,2(OH)]Br or
[N1,4,2(OH),2(OH)]Br, independently of the tested cell model;
however, when [N4,2(OH),2(OH),2(OH)]Br was tested, a great
cytotoxicity in CaCo-2 monolayer was observed, despite
having no significant effect on the other cell line. Following
the same trend, any significant toxicity was quantified for either
[N1,1,6,2(OH)]Br or [N1,6,2(OH),2(OH)]Br, but [N6,2(OH),2(OH),2(OH)]
Br proved to be cytotoxic to Caco-2 cells (data not available
for CRL-1502 cells). Considering this, it is best to use less
hydroxyethyl groups when designing biologically active ILs
because it may potentially increase the cytotoxicity without
conferring any advantage in terms of activity toward AChE, as
mentioned previously.
3.4.1.4. Insertion of Multiple Covalent Bonds. Concerning
the insertion of multiple covalent bonds, we did not obtain any
detectable effect on the viability of the tested cell models
(Table 3).
3.4.1.5. Presence of Morpholine and Cyclohexyl in the
Cation. We did not obtain any detectable effect on monolayer
viability concerning the two cell models used in this study.
3.4.2. Dicationic Cholinium-Based ILs. Similar to ILs from
series A and B, the impact of dicationic cholinium-based ILs on
the cell monolayer was also assessed in normal skin fibroblasts
and colorectal adenocarcinoma epithelial cells.
3.4.2.1. Alkyl-Linkage Chain Length. In agreement with
other works in the literature and with the data obtained for the
monocationic cholinium-based ILs, the cytotoxicity was
enhanced with the length of the alkyl-linkage chain (Table
4).33 Another important conclusion is that DILs are less
cytotoxic than the corresponding monocationic ILs. For
instance, [N1,12,2(OH)]Br was very cytotoxic for CaCo-2 cells,
whereas [N1,12,2(OH)]2Br2 did not significantly affect this model,
and [N1,14,2(OH)]Br induced a great cytotoxicity in CaCo-2
cells, but the corresponding [N1,14,2(OH)]2Br2 was less
deleterious (Table 4). This is in accordance with the
literature.28
3.4.2.2. Addition of Hydroxyethyl Groups. As seen before
for the monocationic ILs, the addition of hydroxyethyl groups
is prone to induce cytotoxicity as is the case of
[N1,12,2(OH),2(OH)]2Br2 and [N12,(OH),2(OH),2(OH)]2Br2, where the
first did not induce a significant decrease in viability,
independently of the cell line. However, the second was very
cytotoxic for both models (Table 4). This is in agreement with
the data obtained for the monocationic cholinium-based ILs.
Additionally, e Silva and co-workers have also published that
dicationic cholinium-based IL toxicity increased on the
luminescent bacteria Vibrio fischeri with the addition of more
hydroxyethyl groups.33 As seen from the biological data
collected from the anti-acetylcholinesterase assay, the presence
of hydroxyethyl groups does not favor the biological activity of
the studied ILs and thus, we conclude that −CH2CH2OH
chains are not beneficial to attain our purposes.
3.4.2.3. Insertion of Acetyl Groups. The protection of the
hydroxyl group with an acetyl group did not produce
detectable difference on the toxicological results (Table 4).
3.4.2.4. Insertion of Benzyl Groups as Spacers. Similarly,
the introduction of two benzyl groups in the linkage did not
seem to produce detectable difference on the toxicological
results (Table 4).
4. CONCLUSIONS
The dicationic cholinium-based ILs are better AChE inhibitors
than the corresponding monocationic analogue. In addition,
DILs with the alkyl linkage of C12−C16 present the most
promising AChE inhibition results. The DIL [N1,1,12,2(OH)]2Br2
shows an IC50 of 0.18 μM without affecting the viability of the
tested cells. To understand the AChE inhibition by
[N1,1,12,2(OH)]2Br2, STD-NMR binding experiments and in
silico molecular docking studies were performed. STD-NMR
clearly demonstrates that [N1,1,12,2(OH)]2Br2 competes with
Figure 3. GOLD docking pose interaction diagram for
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galanthamine for the same binding site of AChE and binds into
the deep gorge active site of AChE. In accordance, molecular
docking shows that [N1,1,12,2(OH)]2Br2 establishes key inter-
actions in both peripheral and catalytic sites of AChE gorge. In
this perspective, our study provides a chemical platform for the
rational design of choline-based ILs as potent AChE inhibitors.
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